Latest News

Metastasis-directed therapy (MDT) in oligometastatic prostate cancer has the potential of delaying the start of androgen deprivation therapy (ADT) and disease progression. We aimed to analyze the efficacy of PSMA-PET/CT in detecting oligometastatic disease (OMD), to look for predictive factors of OMD, and to evaluate the impact of PSMA-PET/CT findings on clinical management.

(UroToday.com) The ANZUP 2021 virtual annual scientific meeting included a presentation by Dr. Sima Porten discussing the use of molecular subtypes in muscle invasive bladder cancer (MIBC) to improve patient selection for treatment. Today’s personalized medicine can be looked at through a variety of lenses:

San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, Ill., from October 24 to 27, 2021. […]

(UroToday.com) The ANZUP 2021 annual scientific meeting included a presentation by Dr. Matthew Galsky discussing the evolving treatment landscape for metastatic urothelial cancer. Dr. Galsky started by highlighting that urothelial carcinoma is not an uncommon malignancy, accounting for 82,000 new diagnoses/year in the United States and ~429,000 new diagnoses/year worldwide. However, until recently, the FDA approvals […]

(UroToday.com) The ANZUP 2021 virtual annual scientific meeting included a presentation by Dr. Eli Van Allen discussing the convergence of machine learning and genomics for precision cancer medicine in genitourinary cancers and beyond. As both a medical oncologist and a clinician he utilizes computational biology to assess canceromic biology for the improvement of cancer outcomes. Dr. […]

High recurrence rates, frequent surveillance strategies and current multidisciplinary treatment approaches make urothelial carcinoma of bladder (UCB) one of the most expensive cancers to clinically manage.

Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity.

Poly(ADP-ribose) polymerase 1 (PARP-1) and glycohydrolase (PARG) enzymes regulate chromatin structure, transcription activation, and DNA repair by modulating poly(ADP-ribose) (pADPr) level. Interest in PARP-1 inhibitors has soared recently with the recognition of their antitumor efficacy.

Circulating lipids or cytokines are associated with prognosis in metastatic castration-resistant prostate cancer (mCRPC). This study aimed to understand the interactions between lipid metabolism and immune response in mCRPC by investigating the relationship between the plasma lipidome and cytokines.

MRI-targeted prostate biopsy improves detection of clinically significant prostate cancer (PCa). However, up to 70% of PCa lesions display intralesional tumor heterogeneity. Current target sampling strategies do not yet adequately account for this finding.